Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti‐inflammatory eicosanoid, lipoxin A4-Reference-Cited by-同舟云学术

Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti‐inflammatory eicosanoid, lipoxin A4

Published:2009-01-05 Issue:5 Volume:23 Page:1503-1509
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Zurier Robert B.¹,Sun Yee‐Ping²,George Kerri L.¹,Stebulis Judith A.¹,Rossetti Ronald G.¹,Skulas Ann¹,Judge Erica¹,Serhan Charles N.²

Affiliation:

1. University of Massachusetts Medical SchoolDivision of RheumatologyWorcesterMassachusettsUSA

2. Center for Experimental Therapeutics and Reperfusion InjuryDepartment of Anesthesia Perioperative and Pain MedicineBrigham and Women's HospitalHarvard Medical SchoolBostonMassachusettsUSA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.08-118323

Reference39 articles.

1. Isolation and Characterization of Two Major Urinary Metabolites of Δ 1 -Tetrahydrocannabinol

2. Cannabinoids. Structure-activity studies related to 1,2-dimethylheptyl derivatives

3. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-up Data from a Three-year Open-Label Extension Study;JID Innovations;2024-09

2. Reorganization of innate immune cell lipid profiles by bioinspired meroterpenoids to limit inflammation;2024-05-28

3. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis;Arthritis & Rheumatology;2023-06-15

4. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial;Journal of Investigative Dermatology;2022-10

5. Potent T cell‐mediated anti‐inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis;Neuropathology and Applied Neurobiology;2021-10-21